ALLERGAN PLC (NYSE:AGN) Files An 8-K Results of Operations and Financial Condition

Item2.02

On May 9, 2017, Allergan plc (the Company) issued a press release
reporting the financial results for the three months ended March
31, 2017. A copy of the press release reporting the financial
results of the Company is attached to this report as Exhibit 99.1
and incorporated herein by reference.

In its press release, the Company discloses items not prepared in
accordance with accounting principles generally accepted in the
United States (GAAP), or non-GAAP financial measures (as defined
in Regulation G promulgated by the U.S. Securities and Exchange
Commission), that exclude certain significant charges or credits
that are important to an understanding of the Companys ongoing
operations. The Company believes that its non-GAAP measures
provide useful information to investors because these are the
financial measures used by our management team to evaluate our
operating performance, make day to day operating decisions,
prepare internal forecasts, communicate external forward looking
guidance to investors, compensate management and allocate the
Companys resources. We believe this presentation also increases
comparability of period to period results. The Companys
determination of significant charges or credits may not be
comparable to similar measures used by other companies and may
vary from period to period. The Company uses both GAAP financial
measures and the disclosed non-GAAP adjusted financial measures
internally. These non-GAAP adjusted financial measures are in
addition to, not a substitute for, or superior to, measures of
financial performance prepared in accordance with GAAP.

Non-GAAP performance net income per share is used by management
as one of the primary metrics in evaluating the Companys
performance. We define non-GAAP performance net income as GAAP
net income / (loss) from continuing operations attributable to
shareholders adjusted for the following net of tax: (i)
amortization expenses, (ii) global supply chain and operational
excellence initiatives, (iii) acquisition, integration and
licensing charges, (iv) accretion and fair market value
adjustments on contingent liabilities, (v) impairment/asset sales
and related costs, including the exclusion of discontinued
operations, (vi) legal settlements and (vii) other unusual
charges or expenses. Non-GAAP performance net income per share is
not, and should not be viewed as, a substitute for reported GAAP
continuing operations loss per share.

We define adjusted EBITDA as an amount equal to consolidated net
income / (loss) from continuing operations attributable to
shareholders for such period adjusted for the following:
(i)interest expense, (ii)interest income, (iii)(benefit) for
income taxes, (iv)depreciation and amortization expenses,
(v)stock-based compensation expense, (vi)asset impairment charges
and losses / (gains) and expenses associated with the sale of
assets, including the exclusion of discontinued operations,
(vii)business restructuring charges associated with Allergans
global supply chain and operational excellence initiatives or
other restructurings of a similar nature, (viii)costs and charges
associated with the acquisition of businesses and assets
including, but not limited to, milestone payments, integration
charges, other charges associated with the revaluation of assets
or liabilities and charges associated with the revaluation of
acquisition related contingent liabilities that are based in
whole or in part on future estimated cash flows, (ix)litigation
charges and settlements and (x)other unusual charges or expenses.
We define non-GAAP adjusted operating income as adjusted EBITDA
including depreciation and certain stock-based compensation
charges, but excluding dividend income.

The information in this report (including the exhibits) is
furnished to Item2.02 and shall not be deemed to be filed for
purposes of Section18 of the Securities Exchange Act of 1934 (the
Exchange Act), nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933 or the Exchange
Act, except as shall be expressly set forth by specific reference
in such filing.

ALLERGAN PLC (NYSE:AGN) Recent Trading Information

ALLERGAN PLC (NYSE:AGN) closed its last trading session down -2.99 at 241.95 with 2,709,064 shares trading hands.